Cumulative incidence and magnitude of HHV-6B reactivation stratified by brincidofovir vs placebo for post-HCT prophylaxis. (A-C) Cumulative incidence of any plasma detection of HHV-6B by quantitative polymerase chain reaction in the overall cohort (A) and stratified by high risk (B) or low risk (C) for HHV-6B reactivation. The number of patients at risk in the brincidofovir (BCV) and placebo (PBO) groups are indicated underneath the figures. (D) Proportion of patients with maximum plasma detection of HHV-6B at different viral load thresholds in the BCV and PBO study groups.